This activity is supported by an educational grant from Bausch + Lomb.

Learning Objectives

Upon completion of this activity, participants will be better able to:

Summarize the clinical benefits of PDT in patients with retinal disorders and in those with persistent disease activity.
Design a treatment regimen based on a personalized medicine approach for patients who do not respond adequately to anti-VEGF injections.
Identify methods for effective PDT delivery in clinic settings, including dosing, infusion periods, and determination of treatment size.
Differentiate the benefits of half-fluence PDT and full-fluence PDT on a real-world population.

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation Method

In order to obtain credit, complete the pretest, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:

Internet Explorer 11 for Windows

Edge (recent versions; Chromium-based) for Windows

Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:

4GB+ RAM

Recommended internet speed 5Mbps+

Faculty and Disclosures

Jordana G. Fein, MD, MS

Staff Physician, The Retina Group of Washington
Fairfax, Virginia

Rishi P. Singh, MD

Staff Physician, Cole Eye Institute
Medical Director, Clinical Systems Office Cleveland Clinic
Associate Professor of Ophthalmology, Case Western Reserve University
Cleveland, Ohio

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Jordana G. Fein, MD, MS, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Apellis, Lexitas, Opthea, and Regeneron Pharmaceuticals. Speaker’s Bureau: Regeneron Pharmaceuticals.

Rishi P. Singh, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Bausch + Lomb, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Apellis and Graybug.

The Evolve staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Bausch + Lomb.

Forget your password?

Video Resources

Back Next

Test

Instructions

In order to obtain credit, complete the pretest, proceed through the program, complete the post-test, evaluation and submit for credit.

Step 1 of 2

1. Based on this activity, please rate your confidence in your ability to use photodynamic therapy (PDT) in the clinic (*based on a scale of 1 to 5, with 1 being not at all confident and 5 being extremely confident).*
a. 1 b. 2 c. 3 d. 4 e. 5
2. Please rate how often you intend to use PDT (*based on a scale of 1 to 5, with 1 being never and 5 being always.)*
a. 1 b. 2 c. 3 d. 4 e. 5
3. In which diseases is PDT a reasonable treatment option?*
- a. Peripapillary choroidal neovascularization
- b. Central serous chorioretinopathy
- c. Choroidal neovascular membrane lesions
- d. Ocular tumors
- e. All of the above
4. All but which of the following statements is true?*
- a. Half fluence PDT can be achieved by reducing power of laser
- b. Half fluence PDT can be achieved by increasing the laser time
- c. Full fluence PDT may be most appropriate for choroidal hemangioma treatment
- d. Half dose PDT is may reduce risks of severe vision decrease
5. To determine the treatment size for PDT using traditional guidelines, how far beyond the greatest linear diameter of the lesion should you measure?*
- a. 4,000 μm
- b. 3,000 μm
- c. 2,000 μm
- d. 1,000 μm
6. Post-PDT, what is the minimum number of days a patient should avoid direct sunlight?*
- a. 2 days
- b. 3 days
- c. 4 days
- d. 5 days
7. PLANET evaluated PDT as a potential rescue therapy for patients with polypoidal choroidal vasculopathy (PCV) who had a suboptimal response to aflibercept. What did the findings suggest?*
- a. Ranibizumab is a better anti-VEGF agent to pair with PDT for patients with PCV.
- b. Aflibercept/PDT combination was superior to aflibercept monotherapy, suggesting patients should be treated immediately with the combination particularly in the setting of an active hemorrhage.
- c. Aflibercept monotherapy was shown to be noninferior to aflibercept/PDT, suggesting aflibercept may be an efficacious anti-VEGF therapy for PCV.
- d. Patients with PCV do not benefit from rescue injections of PDT.
8. After 3 months, an elderly patient with anti-VEGF-resistant wet AMD treated with half fluence PDT has had no response but not vision has not worsened from the treatment. What is your next step(s)? (*Select all that apply)*
- a. Continue to watch the patient; they need more time for the treatments to be considered successful or non-respondent.
- b. Retreat the patient with full-fluence PDT.
- c. Retreat the patient with partial-fluence PDT.
- d. Treat the patient with a micropulse laser.
9. The Verteporfin in Photodynamic Therapy Study Group found ________ of patients could have acute vision loss after PDT.*
- a. 1%
- b. 2%
- c. 3%
- d. 4%
10. What is a likely scenario for a patient who has undergone PDT for chronic CSR?*
- a. Immediately anatomic response
- b. Anatomic response at 1 week, vision improvement within 1 to 2 weeks
- c. Anatomic improvement after 2 months or longer, vision improvement is more variable
- d. Vision improvement around 1 month; anatomic improvement is more variable
Profession:*
- MD/DO
- NP
- Nurse/APN
- PA
- OD
- Other
Years in Practice:*
- >20
- 11-20
- 6-10
- 1-5
- <1
Patients Seen Per Week (with the disease targeted in this activity):*
- 0
- 1-15
- 16-30
- 31-50
- 50+
Region:*
- Northeast
- Northwest
- Midwest
- Southeast
- Southwest
Setting:*
- Solo Practice
- Community Hospital
- Government or VA
- Group Practice
- Other
- I do not actively practice
Models of Care:*
- Fee for Service
- ACO
- Patient-Centered Medical Home
- Capitation
- Bundled Payments
- Other

Did the program meet the following educational objectives?*

	Agree	Neutral	Disagree
Summarize the clinical benefits of PDT in patients with retinal disorders and in those with persistent disease activity
Design a treatment regimen based on a personalized medicine approach for patients who do not respond adequately to anti-VEGF injections
Identify methods for effective PDT delivery in clinic settings, including dosing, infusion periods, and determination of treatment size
Differentiate the benefits of half-fluence PDT and full-fluence PDT on a real-world population

	Yes	No
The design of the program was effective for the content conveyed
The content supported the identified learning objectives
The content was free of commercial bias
The content was relative to your practice
The faculty was effective
You were satisfied overall with the activity
Would you recommend this program to your colleagues

Specialty

Course Type

Specialty

Course Type

Search

Menu

Specialty

Course Type

Search

Menu

Photodynamic Therapy: A Look at How This Treatment Fits Into Today’s Retina Practice

Webinar Credits: 1

Expiration Date: Wednesday, June 30, 2021

Release Date: July 7, 2020

Learning Objectives

Accreditation and Designation Statement

Participation Method

Faculty and Disclosures

Disclaimer

Video Resources

Test

Instructions

Step 1 of 2

Photodynamic Therapy: A Look at How This Treatment Fits Into Today’s Retina Practice

Webinar Credits: 1

Expiration Date: Wednesday, June 30, 2021

Release Date: July 7, 2020

Learning Objectives

Accreditation and Designation Statement

Participation Method

Faculty and Disclosures

Disclaimer

Please log in to view this course

Video Resources

Test

Instructions

Step 1 of 2